手术治疗的HPV相关口咽癌循环肿瘤HPV DNA的决定因素
该回顾性队列研究纳入104例接受 upfront 手术的HPV相关口咽鳞癌患者,分析术前和术后循环肿瘤HPV DNA(ctHPVDNA)与临床病理变量的关联。多变量分析显示,较高的eGFR和较高的病理N分期与较高的术前ctHPVDNA水平独立相关,而神经周围侵犯和病理结外延伸与较低水平相关。术后可检测到ctHPVDNA见于20.2%的患者,与超过4个阳性淋巴结和较高的术前ctHPVDNA水平相关。
要点
- 较高的病理N分期和eGFR与术前ctHPVDNA水平升高独立相关。
- 神经周围侵犯和病理结外延伸与较低的术前ctHPVDNA水平相关。
- 术后可检测ctHPVDNA见于20.2%的患者,与阳性淋巴结数目和术前水平相关。
核心结论
- 术前ctHPVDNA水平与病理N分期、eGFR、神经周围侵犯和病理结外延伸独立相关。
- 术后可检测ctHPVDNA与超过4个阳性淋巴结及较高的术前ctHPVDNA水平相关。
研究设计与样本
- 回顾性队列研究,在三级学术医疗中心进行,纳入2021年9月至2025年4月接受 upfront 手术的HPV相关口咽鳞癌患者。
- 共104例患者有术前ctHPVDNA测量,其中74例有术前和术后评估。
主要发现
- 术前ctHPVDNA平均(SD)水平为2786(9714)拷贝/mL。
- 多变量负二项回归显示,较高的eGFR(RR=1.05,95%CI 1.01-1.09)和较高的病理N分期(RR=12.30,95%CI 2.65-57.5)与较高的术前ctHPVDNA水平独立相关。
- 神经周围侵犯(RR=0.23,95%CI 0.07-0.83)和病理结外延伸(RR=0.11,95%CI 0.04-0.28)与较低的术前ctHPVDNA水平相关。
- 术后可检测ctHPVDNA见于15/74例(20.2%),与超过4个阳性淋巴结(OR=4.86,95%CI 1.39-19.49)和较高的术前ctHPVDNA水平(OR=1.17,95%CI 1.04-1.36)相关。
- 术后可检测ctHPVDNA患者中3/15例(20.0%)复发,而术后不可检测患者中8/59例(13.6%)复发。
临床怎么用
- 术前ctHPVDNA水平受肾功能、病理N分期、神经周围侵犯和结外延伸影响,解读时需考虑这些因素。
- 术后可检测ctHPVDNA与高危病理特征相关,可能有助于识别复发风险较高的患者。
局限性
- 回顾性研究设计。
- 单中心研究。
- 部分患者缺乏术后ctHPVDNA数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Circulating tumor DNA (ctDNA) is a biomarker of disease status in patients with human papillomavirus (HPV)-mediated oropharyngeal squamous cell carcinoma (OPSCC). OBJECTIVE: To assess clinicopathologic variables associated with circulating tumor human papillomavirus DNA (ctHPVDNA) before and after surgery. DESIGN, SETTING, AND PARTICIPANTS: The retrospective review and cohort study was conducted at a tertiary academic medical center and included patients with HPV-mediated OPSCC who were treated with upfront surgery between September 2021 and April 2025. Data were analyzed between September 2025 and December 2025. EXPOSURES: Clinicopathologic variables, including demographic characteristics, pathologic T and N stage, American Joint Committee on Cancer Staging Manual, 8th edition stage, tumor size, margin status, pathologic extranodal extension (pENE), and lymphovascular and perineural invasion. MAIN OUTCOMES AND MEASURES: Multivariable negative binomial regression was used to identify clinicopathologic factors associated with preoperative ctHPVDNA, which was measured using tumor tissue-modified viral HPV DNA. Factors associated with detectable postoperative ctHPVDNA were evaluated using logistic regression. RESULTS: A total of 104 patients (mean [SD] age, 59 [10] years; 20 female individuals [19%] and 84 male individuals [81%]; 3 Black individuals [3%] and 101 White individuals [97%]) with HPV-associated OPSCC who were treated with upfront surgery had preoperative ctHPVDNA measurements, and 74 patients had preoperative and postoperative assessments. The mean (SD) preoperative ctHPVDNA level was 2786 (9714) copies/mL. On multivariable negative binomial regression, higher estimated glomerular filtration rate (eGFR; rate ratio [RR], 1.05; 95% CI, 1.01-1.09) and higher pathologic N stage (RR, 12.30; 95% CI, 2.65-57.5) were independently associated with higher preoperative ctHPVDNA levels, whereas perineural invasion (PNI; RR, 0.23; 95% CI, 0.07-0.83) and pathologic extranodal extension (pENE; RR, 0.11; 95% CI, 0.04-0.28) were associated with lower levels. Detectable postoperative ctHPVDNA was observed in 15 of 74 patients (20.2%) and was associated with more than 4 positive lymph nodes (odds ratio [OR], 4.86; 95% CI, 1.39-19.49) higher preoperative ctHPVDNA levels (OR, 1.17; 95% CI, 1.04-1.36), PNI (OR, 2.95; 95% CI, 0.51- 15.51), and pENE (OR, 3.38; 95% CI, 0.84-13.29). Recurrence occurred for 3 of 15 patients (20.0%) with detectable postoperative ctHPVDNA compared with 8 of 59 patients (13.6%) with undetectable ctHPVDNA. Among patients with undetectable postoperative ctHPVDNA, 4 locoregional recurrences occurred in individuals who declined guideline-concordant adjuvant therapy. CONCLUSIONS AND RELEVANCE: The results of this cohort study illuminate the biological and clinical factors associated with ctHPVDNA shedding and clearance, potentially offering guidance for integrating ctHPVDNA into biomarker-driven clinical trials.
引用
- Birkenbeuel JL, Noel C, Baliga S, et al. Determinants of Circulating Tumor HPV DNA in Surgically Treated Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 41926134. doi:10.1001/jamaoto.2026.0015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。